TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02823587

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary Rehabilitation
Description: The exercise program will consist of an individual exercise prescription on the treadmill or bike, the initial intensity of 85% VO2max and active exercises or active-resistance for upper and lower limbs according to the capacity of each volunteer.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary Rehabilitation
Description: The exercise program will consist of an individual exercise prescription on the treadmill or bike, the initial intensity of 85% VO2max and active exercises or active-resistance for upper and lower limbs according to the capacity of each volunteer.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control
Description: No supervised exercise session, only will be informed at the beginning of the study to perform thirty minutes of physical activity of moderate intensity several days a week is associated with health benefits

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control
Description: No supervised exercise session, only will be informed at the beginning of the study to perform thirty minutes of physical activity of moderate intensity several days a week is associated with health benefits
Study: NCT04520087

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allograft fixation
Description: Patients with anteroinferior shoulder instability will be clinically treated with a mini-open arthrotomic technique involving the fixation of the corticospongeous bone graft on the glena.
Study: NCT01293682

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcitriol
Description: In pill form, 45 micrograms once a week for 12 weeks
Study: NCT03700515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythropoietin
Description: Subjects receive weekly infusions of EPO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythropoietin
Description: Subjects receive weekly infusions of EPO

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects receive weekly infusions of saline
Study: NCT03488537

Intervention type: DEVICE
Group type: OTHER
Intervention: AeonoseTM
Description: Breath test
Study: NCT03258515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6094 200 mg
Description: A potent and selective small molecule mesenchymal epithelial transition (MET) kinase inhibitor with significant antitumor activity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6094 200 mg
Description: A potent and selective small molecule mesenchymal epithelial transition (MET) kinase inhibitor with significant antitumor activity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6094 200 mg
Description: A potent and selective small molecule mesenchymal epithelial transition (MET) kinase inhibitor with significant antitumor activity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6094 200 mg
Description: A potent and selective small molecule mesenchymal epithelial transition (MET) kinase inhibitor with significant antitumor activity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6094 200 mg
Description: A potent and selective small molecule mesenchymal epithelial transition (MET) kinase inhibitor with significant antitumor activity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6094 200 mg
Description: A potent and selective small molecule mesenchymal epithelial transition (MET) kinase inhibitor with significant antitumor activity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: AZD6094 matching placebo without any pharmacological activity.
Study: NCT02175069

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadopentetate-Dimeglumine 0.0125 mmol
Description: 0.0125 mmol of gadopentetate-dimeglumine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gadopentetate-Dimeglumine 0.05 mmol
Description: 0.05 mmol of gadopentetate-dimeglumine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.75%, 5ml
Description: 5 ml of ropivacaine 0.75%

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Shoulder Surgery
Description: As per individual requirement (patient-dependent)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Shoulder Surgery
Description: As per individual requirement (patient-dependent)
Study: NCT00754247

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5% hydrocortisone, silicone, vitamin E lotion
Description: 0.5% hydrocortisone, silicone, vitamin E lotion will be applied topically to cover the selected scar twice daily for 16 weeks. The lesion will be cleansed with soap and water and dried thoroughly. The medication will be applied with a brush and allow it to dry for one minute before contact with clothing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Onion extract gel
Description: Onion extract gel is applied and massaged into the selected scar 3 to 4 times daily according to product instructions for 16 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cetearyl alcohol lotion
Description: Placebo is cetearyl alcohol lotion with no steroids, silicone, vitamin E, or onion extract and will be applied 2 times a day to the lesion.
Study: NCT01743092

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Webinar
Description: Some clients will receive a webinar as part of their treatment.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Tutuorial workbook
Description: A work book about their addiciton

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tutuorial workbook
Description: A work book about their addiciton
Study: NCT02421458

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 6 x 6 Gy
Description: radiation in 6 fraction of 6 Gy, twice a week during 3 weeks

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 16 x 3.125 Gy
Description: radiation in 16 fraction of 3.125 Gy, 4 times a week during 4 weeks
Study: NCT03258515

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: AZD6094 matching placebo without any pharmacological activity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: AZD6094 matching placebo without any pharmacological activity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: AZD6094 matching placebo without any pharmacological activity.
Study: NCT06574230

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TRAINING PROGRAM
Description: Each training session included a structured set of exercises aimed at enhancing these skills. For example, participants practiced precision drills to target specific areas of the dartboard, endurance drills to build stamina for longer games, and competitive exercises to simulate real-game conditions. This combination of theoretical knowledge, practical skill development, and strategic gameplay was designed to comprehensively improve the participants\&#39; dart-throwing abilities over the course of the program. A 12-week dart training program, with sessions conducted three times per week, each lasting 90 minutes. In the first week, participants received comprehensive theoretical and practical instruction covering the rules of the game, proper breathing techniques, and throwing mechanics. This initial phase was designed to ensure a solid understanding of the fundamentals before progressing to more advanced training.
Study: NCT06410872

Intervention type: DIAGNOSTIC_TEST
Intervention: BART Task
Description: The Zuckerman's Sensation Seeking Scale version-V (SSS-V) - Four-factor score, The Barret Impulsiveness Scale (BIS), Gormally's Binge Eating Scale (BES), The World Health Organization-developed AUDIT (Alcohol Use Disorders Identification Test) screen, The CAGE questionnaire for substance abuse-adapted to include drugs, Gamblers Anonymous's 20 Questions (GA20), Hospital Anxiety and Depression Scale (HADS)

Intervention type: DIAGNOSTIC_TEST
Intervention: BART Task
Description: The Zuckerman's Sensation Seeking Scale version-V (SSS-V) - Four-factor score, The Barret Impulsiveness Scale (BIS), Gormally's Binge Eating Scale (BES), The World Health Organization-developed AUDIT (Alcohol Use Disorders Identification Test) screen, The CAGE questionnaire for substance abuse-adapted to include drugs, Gamblers Anonymous's 20 Questions (GA20), Hospital Anxiety and Depression Scale (HADS)

Intervention type: DIAGNOSTIC_TEST
Intervention: BART Task
Description: The Zuckerman's Sensation Seeking Scale version-V (SSS-V) - Four-factor score, The Barret Impulsiveness Scale (BIS), Gormally's Binge Eating Scale (BES), The World Health Organization-developed AUDIT (Alcohol Use Disorders Identification Test) screen, The CAGE questionnaire for substance abuse-adapted to include drugs, Gamblers Anonymous's 20 Questions (GA20), Hospital Anxiety and Depression Scale (HADS)

Intervention type: DIAGNOSTIC_TEST
Intervention: BART Task
Description: The Zuckerman's Sensation Seeking Scale version-V (SSS-V) - Four-factor score, The Barret Impulsiveness Scale (BIS), Gormally's Binge Eating Scale (BES), The World Health Organization-developed AUDIT (Alcohol Use Disorders Identification Test) screen, The CAGE questionnaire for substance abuse-adapted to include drugs, Gamblers Anonymous's 20 Questions (GA20), Hospital Anxiety and Depression Scale (HADS)
Study: NCT03258515

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: AZD6094 matching placebo without any pharmacological activity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: AZD6094 matching placebo without any pharmacological activity.
Study: NCT00134381

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Green Tea
Description: Green tea product (EGCG or caffeine) in vehicle will be applied immediately after and at sequential time points after exposure of a 5x5-cm area of skin to a dose of UVB that is 0.5-2 times the subject's minimal erythema dose (MED)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (vehicle alone) will be applied immediately after and at sequential time points after exposure of a 5x5-cm area of skin to a dose of UVB that is 0.5-2 times the subject's minimal erythema dose (MED)
Study: NCT03258515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: A fluoroquinolone broad-spectrum antibiotic, produces a mild, but reproducible increase in QT interval corrected (QTc) in healthy normal participants at time to reach maximum concentration (tmax - approximately 2 hours (0.5 to 4 hours)). This effect is close to the ECG interval measured from the onset of the QRS complex (onset of the QRS complex to the J point) to the offset of the T wave (QT)/QTc effect that represents the threshold of regulatory concern, around 5 ms mean QTc interval prolongation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: A fluoroquinolone broad-spectrum antibiotic, produces a mild, but reproducible increase in QT interval corrected (QTc) in healthy normal participants at time to reach maximum concentration (tmax - approximately 2 hours (0.5 to 4 hours)). This effect is close to the ECG interval measured from the onset of the QRS complex (onset of the QRS complex to the J point) to the offset of the T wave (QT)/QTc effect that represents the threshold of regulatory concern, around 5 ms mean QTc interval prolongation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: A fluoroquinolone broad-spectrum antibiotic, produces a mild, but reproducible increase in QT interval corrected (QTc) in healthy normal participants at time to reach maximum concentration (tmax - approximately 2 hours (0.5 to 4 hours)). This effect is close to the ECG interval measured from the onset of the QRS complex (onset of the QRS complex to the J point) to the offset of the T wave (QT)/QTc effect that represents the threshold of regulatory concern, around 5 ms mean QTc interval prolongation.
Study: NCT05548608

Intervention type: OTHER
Intervention: Reposition error (RE), pain at target positions of RE and flexibility of the TLF were assesed with iphone tiltmeter app, VAS and goniometric platform, respectively.
Description: Target positions of reposition error were: 30º forward bending and 15º backward bending in sitting and standing.

Intervention type: OTHER
Intervention: Reposition error (RE), pain at target positions of RE and flexibility of the TLF were assesed with iphone tiltmeter app, VAS and goniometric platform, respectively.
Description: Target positions of reposition error were: 30º forward bending and 15º backward bending in sitting and standing.

Intervention type: OTHER
Intervention: Reposition error (RE), pain at target positions of RE and flexibility of the TLF were assesed with iphone tiltmeter app, VAS and goniometric platform, respectively.
Description: Target positions of reposition error were: 30º forward bending and 15º backward bending in sitting and standing.
Study: NCT01158222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib malate
Description: Given orally
Study: NCT00632697

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pentoxifylline
Description: 800 mg daily for six months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT00594828

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CoaguChek (Patient self testing)
Description: Patients will test their INR at home either biweekly, weekly or every 2 weeks using a CoaguChek point of care meter and communicate with the healthcare provider via an internet based expert system

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Anticoagulation Management Service (AMS)
Description: Patients will attend the AMS for six months and have their INR checked every 4-6 weeks or more frequently, at the discretion of the clinician
Study: NCT04264286

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prophylactic esmolol
Description: Patients will receive prophylactic esmolol after the end of the surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will prophylactic placebo after the end of the surgery
Study: NCT03962335

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Vegetarian diet
Description: 7-days dietary profile with a Vegetarian diet (VD), containing inulin and resistant starch-rich foods and including no meat and fish, but containing eggs and dairy, for 3 months

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vegetarian diet
Description: 7-days dietary profile with a Vegetarian diet (VD), containing inulin and resistant starch-rich foods and including no meat and fish, but containing eggs and dairy, for 3 months

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vegetarian diet
Description: 7-days dietary profile with a Vegetarian diet (VD), containing inulin and resistant starch-rich foods and including no meat and fish, but containing eggs and dairy, for 3 months

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mediterranean diet with butyrate
Description: 7-days dietary profile with Mediterranean diet with oral supplementation with butyrate (MD+Bt), 2 g/day, for 3 months

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mediterranean diet with butyrate
Description: 7-days dietary profile with Mediterranean diet with oral supplementation with butyrate (MD+Bt), 2 g/day, for 3 months

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mediterranean diet with butyrate
Description: 7-days dietary profile with Mediterranean diet with oral supplementation with butyrate (MD+Bt), 2 g/day, for 3 months

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mediterranean diet
Description: 7-days dietary profile with Mediterranean diet (MD), including 2 portions per week of fish and 3 portions per week of fresh and processed meat (2 of which fresh or processed red meat), for 3 months

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Description: 7-days dietary profile with Mediterranean diet (MD), including 2 portions per week of fish and 3 portions per week of fresh and processed meat (2 of which fresh or processed red meat), for 3 months

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Description: 7-days dietary profile with Mediterranean diet (MD), including 2 portions per week of fish and 3 portions per week of fresh and processed meat (2 of which fresh or processed red meat), for 3 months
Study: NCT03584672

Intervention type: OTHER
Intervention: Static Balance Test
Description: Balance control is assessed by the Static Balance Test.

Intervention type: OTHER
Intervention: Static Balance Test
Description: Balance control is assessed by the Static Balance Test.

Intervention type: OTHER
Intervention: Berg Balance Scale
Description: Functional balance is assessed by the Berg Balance Scale.

Intervention type: OTHER
Intervention: Timed Up an Go Test
Description: Functional mobility is assessed by the Timed Up and Go test.

Intervention type: OTHER
Intervention: Four Square Step Test
Description: Dynamic balance is assessed by the Four Square Step Test.

Intervention type: OTHER
Intervention: Functional Reach Test
Description: Limits of stability is assessed by the Functional Reach Test.

Intervention type: OTHER
Intervention: One-leg Stance Test
Description: Postural steadiness is assessed by the One-leg Stance Test.
Study: NCT02760134

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Super-Mini Percutaneous Nephrolithotomy
Description: Patients undergo Super-Mini Percutaneous Nephrolithotomy

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Super-Mini Percutaneous Nephrolithotomy
Description: Patients undergo Super-Mini Percutaneous Nephrolithotomy
Study: NCT01529528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anagliptin
Description: Anagliptin 100mg, tablet, BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anagliptin
Description: Anagliptin 100mg, tablet, BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of Anagliptin
Description: Placebo of Anagliptin 100mg, tablet, BID
Study: NCT01917071

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: thoracic spine manipulation
Description: a manual technique applied to the mid back to promote motion
Study: NCT03258515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: A fluoroquinolone broad-spectrum antibiotic, produces a mild, but reproducible increase in QT interval corrected (QTc) in healthy normal participants at time to reach maximum concentration (tmax - approximately 2 hours (0.5 to 4 hours)). This effect is close to the ECG interval measured from the onset of the QRS complex (onset of the QRS complex to the J point) to the offset of the T wave (QT)/QTc effect that represents the threshold of regulatory concern, around 5 ms mean QTc interval prolongation.
Study: NCT01178229

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: The physiotherapeutic intervention was based on the Awareness through Movement technique. Ten sessions were planed. Each session lasted three hours.~The children of the experimental group and their parents were guided by two physiotherapist and the sessions took place in a room rounded by mirrors.~Each session developed as follows: presentation to the parents of the somatic awareness technique for each day; movements, games, motor tales and exercises performed by the children; in each session, a guide book with cartoons was given to the children and their parents to reinforce the exercises at home to keep a long-term result.~All the children assisted together to all the sessions and the instructions and instruments given to the children and their parents were the same for all of them.
Study: NCT01187082

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: bladdertraining in groups
Description: Cognitive training in groups of 4 patients at hospital by a continence nurse in 3 sessions (1 hour)over a period of 1 month. Follow up after 1 month. During all 2 month the patient has selfinitiatied daily training with a pocket bladder schedule.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: bladdertraining individually
Description: Cognitive training individually at hospital by a continence nurse in 3 sessions (1 hour)over a period of 1 month. Follow up after 1 month. During all 2 month the patient has selfinitiatied daily training with a pocket bladder schedule.
Study: NCT05188352

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chest physiotherapy
Description: The program included diaphragmatic breathing exercises, thoracic expansion exercises, incentive spirometer exercises, and coughing techniques.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chest physiotherapy
Description: The program included diaphragmatic breathing exercises, thoracic expansion exercises, incentive spirometer exercises, and coughing techniques.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training
Description: A treadmill was used for aerobic exercise. Training intensity was used at 60-75% of maximal VO2.~Each session had a five-minute warm-up and cool-down period. Blood pressure and ECG were recorded during training sessions before exercise, at the third minute of each workload, after exercise, and during each minute of the recovery period.
Study: NCT04655911

Intervention type: BIOLOGICAL
Intervention: ABO-101
Description: Gene therapy rAAV9.CMV.hNAGLU
Study: NCT01715103

Intervention type: PROCEDURE
Group type: OTHER
Intervention: vaginal swabs by washing and cytobrush
Description: vaginal swabs by washing and cytobrush

Intervention type: PROCEDURE
Group type: OTHER
Intervention: vaginal swabs by washing and cytobrush
Description: vaginal swabs by washing and cytobrush
Study: NCT00219934

Intervention type: DRUG
Intervention: Antiretroviral therapy
Description: HAART therapy

Intervention type: DRUG
Intervention: Antiretroviral therapy
Description: HAART therapy
Study: NCT03040297

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tracheal gas insufflation 6 L/min
Description: Endotracheal flow (6 L/min) of respiratory gases with standard FiO2

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tracheal gas insufflation 11 L/min
Description: Endotracheal flow (11 L/min) of respiratory gases with standard FiO2

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tracheal gas insufflation catheter, without gas flow
Description: Tracheal gas insufflation catheter, without gas flow
Study: NCT04549948

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 0.021X0.025 B-Titanium archwire
Description: Leveling curve of Sppe using 0.019X0.025 B-Titanium archwire
Study: NCT04513041

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pinhole surgical technique and tunnel technique in a split mouth design
Description: Each subject will have the each surgical procedure which are both considered routine minimally invasive clinical care for gingival recession. Gum recession on one side will receive Pinhole surgical technique (test procedure). The other side will receive Tunnel technique (control procedure), Research component involved is the capture of digital impression using intra-oral scanner in the baseline (preoperative) and the final visit (6 months postoperative).